Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4,078.95% | -23.87% | -23.47% | -15.75% | -29.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3,527.19% | -18.34% | -13.04% | -13.54% | -31.41% |
| Operating Income | -3,527.19% | 18.34% | 13.04% | 13.54% | 31.41% |
| Income Before Tax | -2,261.75% | 36.30% | 22.62% | 30.13% | 20.70% |
| Income Tax Expenses | 99.84% | 99.61% | 0.54% | 0.54% | 2.30% |
| Earnings from Continuing Operations | -2,398.21% | 33.02% | 23.81% | 31.57% | 21.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,398.21% | 33.02% | 23.81% | 31.57% | 21.56% |
| EBIT | -3,527.19% | 18.34% | 13.04% | 13.54% | 31.41% |
| EBITDA | -3,528.64% | 18.31% | 12.99% | 13.48% | 31.38% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |